Holen Sie sich die Stockscreener-App
0.9604
3.14%
-0.0311
Handel nachbörslich:
.97
0.0096
+1.00%
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India
FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World
Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace
Rallybio Narrows Losses 37%, Advances RLYB212 Trial with $75M Cash Runway | RLYB Stock News - StockTitan
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice
Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada
Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada
Rallybio advances novel FNAIT prevention trial - Investing.com India
Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks
Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia
Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com
Rallybio shares hold Buy rating on HPP treatment data - Investing.com India
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan
Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia
Rallybio reveals higher FNAIT risk across populations - Investing.com
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire
Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Rallybio announces board member resignation - Investing.com
Rallybio announces board member resignation By Investing.com - Investing.com UK
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks
Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
Rallybio - FiercePharma
Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com
Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St
Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia
HC Wainwright Comments on Rallybio Co.’s Q3 2024 Earnings (NASDAQ:RLYB) - Defense World
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):